Episode Details
Back to Episodes
Daily Roundup | Novo Seeks Injunction on Lilly Obesity Ads: The Comparative Claims Precedent
Published 1 month, 3 weeks ago
Description
Novo Nordisk is asking a court to shut down Eli Lilly'scomparative obesity ads — an injunction bid that could reset the rules for GLP-1 promotion industry-wide. Also: Sanofi ends amlitelimab development in atopic dermatitis, Ipsen's Bylvay fails the Phase 3 BOLD trial in biliary atresia, CHMP recommends NewAmsterdam Pharma and Menarini's obicetrapib and its ezetimibe combination in Europe, the FDA's peptide advisory panel splits itsvotes, Amgen fights to keep Tavneos on the market, Lilly moves to file retatrutide, and Arrowhead posts best-case triglyceride data.
Visit us at thepharmacloseout.com.